Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)

Analyst Ratings

Consensus Ratings for Paratek Pharmaceuticals (NASDAQ:PRTK) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $38.43 (198.59% upside)

Analysts' Ratings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016BTIG ResearchReiterated RatingBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Robert W. BairdReiterated RatingOutperform$30.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Ladenburg ThalmannBoost Price TargetBuy$46.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016HC WainwrightBoost Price TargetBuy$31.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2016Leerink SwannReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015GuggenheimReiterated RatingBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015GabelliInitiated CoverageBuy$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/2/2016($1.25)($1.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($1.18)($1.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.91)($1.33)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.75)($0.94)$3.62 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/18/2015Q1($2.16)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014($0.18)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.21)($0.29)$0.50 million$0.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.42)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2012Q312$0.06$0.25$8.37 million$10.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($1.29)($1.29)($1.29)
Q2 20162($1.64)($1.32)($1.48)
Q3 20162($1.38)($1.36)($1.37)
Q4 20162($1.39)($1.28)($1.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Paratek Pharmaceuticals (NASDAQ:PRTK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
5/14/2014special$1.336/4/20145/26/20146/3/2014Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/27/2016Fund Iv L.P. OmegaMajor ShareholderBuy461,538$13.00$5,999,994.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2016Michael BighamCEOBuy20,000$13.45$269,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Evan LohCMOBuy2,300$16.87$38,801.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015Hbm Healthcare Investments (CaMajor ShareholderSell20,580$30.75$632,835.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Roumell Asset Management, Llcmajor shareholderSell1,470$3.54$5,203.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2013Roumell Asset Management, Llcmajor shareholderSell10,490$3.55$37,239.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Roumell Asset Management, Llcmajor shareholderSell8,710$3.54$30,833.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Roumell Asset Management, Llcmajor shareholderSell7,120$3.50$24,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Roumell Asset Management, Llcmajor shareholderSell10,040$3.57$35,842.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013Roumell Asset Management, Llcmajor shareholderSell7,190$3.53$25,380.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Roumell Asset Management, Llcmajor shareholderSell4,960$3.61$17,905.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Roumell Asset Management, LlcMajor ShareholderSell7,020$3.69$25,903.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateHeadline
07/22/16 05:47 PMParatek Pharmaceuticals : Announces Closing of Common Stock Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
07/22/16 08:54 AMEarnings Focus and Crowd Sourced Sentiment Review for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - TGP
07/22/16 08:54 AMParatek Pharmaceuticals, Inc. (PRTK) Current Analyst Ratings ... - Fiscal Standard
07/20/16 08:48 AMParatek Pharmaceuticals, Inc. (NASDAQ:PRTK): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 08:48 AMNew Broker Ratings For Paratek Pharmaceuticals, Inc. (PRTK) - FTSE News
07/18/16 06:02 PMTrading Performance and Target Watch for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Press Telegraph
07/18/16 06:02 PMParatek Pharmaceuticals Inc's Trend Down, Especially After Forming a Multiple Bottom - Press Telegraph
07/16/16 09:13 AMFlagstar Bancorp Inc. (NYSE:FBC) Rose 0.04%: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), NuVasive, Inc ... - KC Register
07/16/16 09:13 AMBroker Outlook For Paratek Pharmaceuticals, Inc. (PRTK) - Fiscal Standard
07/14/16 09:34 AMCrowd Rating and Earnings Recap for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Telanagana Press
07/13/16 06:21 PMAnalyst Target and Average Rating Watch: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Press Telegraph
07/12/16 10:20 AMParatek Pharmaceuticals Incorporated (NASDAQ:PRTK) Shorted Shares Decreased By 6.44% - Press Telegraph
07/09/16 09:04 AMHow Many Paratek Pharmaceuticals Inc (NASDAQ:PRTK)'s Analysts Are Bearish? - Press Telegraph
07/05/16 10:25 AMMost recent Analysts Rating report: Seattle Genetics, Inc. (NASDAQ:SGEN) , Paratek Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/04/16 05:08 PMParatek Pharmaceuticals, Inc. (PRTK) Broker Price Targets For The Coming Week - Fiscal Standard
06/30/16 06:11 PMSell-Side Recommendation & Price Target Projections on Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Telanagana Press
06/29/16 08:43 AMParatek Pharmaceuticals : Announces Closing of Common Stock Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares
06/28/16 05:51 PMEquity Research and Technical Review on Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Press Telegraph
06/28/16 05:51 PMShare Update and Earnings Review for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Press Telegraph
06/28/16 10:47 AMTuesday 6/28 Insider Buying Report: LNG, PRTK
06/27/16 05:55 PMParatek Pharmaceuticals : Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock
06/27/16 05:55 PMParatek Announces Closing of Common Stock Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
06/26/16 05:01 PMLadenburg Thalmann Maintains Paratek Pharmaceuticals Inc to Buy with Price Target $52.00 - Trade Calls
06/23/16 08:35 AMTwo Movers inside Analysts Radar: Bristol-Myers Squibb Company (NYSE:BMY) , Paratek Pharmaceuticals, Inc ... - Street Updates
06/23/16 08:35 AMParatek Pharmaceuticals, Inc. (NasdaqGM:PRTK) Stock Momentum Hits Weakness - CML News
06/22/16 05:53 PMParatek Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock
06/22/16 04:07 PMPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events -
06/22/16 10:40 AMSizzling Stocks Alert - Whiting Petroleum, (NYSE:WLL), Paratek Pharmaceuticals, (NASDAQ:PRTK) - Hot Stocks Point
06/22/16 10:40 AMParatek Pharmaceuticals (PRTK) Prices 4.25M Common Stock Offering at $13/Share - StreetInsider.com
06/22/16 10:40 AMParatek Pharmaceuticals (NASDAQ:PRTK) Analyst Rating Consensus - Trade Calls
06/21/16 05:30 PMParatek Pharmaceuticals : Announces Proposed Public Offering of Common Stock
06/21/16 10:17 AMParatek Announces Proposed Public Offering of Common Stock
06/20/16 05:42 PMParatek Pharmaceuticals (PRTK) Expects to Present Omadacycline Phase 1b Data in Q416 - StreetInsider.com
06/20/16 07:19 AMParatek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated - [at noodls] - Company to host a webcast and conference call for investors at 4:30 pm EDT to review top-line results BOSTON, June 16, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announces today ...
06/20/16 07:00 AMParatek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 1b Urinary Tract Infection Study - [GlobeNewswire] - BOSTON, June 20, 2016-- Paratek Pharmaceuticals, Inc. announced today that it projects its ongoing phase 1 b clinical study evaluating omadacycline in the treatment of uncomplicated urinary tract infections ...
06/19/16 09:46 AMParatek Spikes On Study Results
06/19/16 09:46 AMParatek Pharmaceuticals Inc. (PRTK) Is Rising On Phase 3 Study News
06/18/16 10:05 AMHome Biotech Stocks Paratek Pharmaceuticals, Inc. | $PRTK Stock | Shares Spike Up On Positive... - TickerTV News (press release)
06/17/16 05:44 PMBuzz Stocks: Smith & Wesson Holding Corp, Paratek Pharmaceuticals Inc, and Lumber Liquidators Holdings Inc - Schaeffers Research (blog)
06/17/16 11:19 AMParatek Pharmaceuticals Announces Positive Phase 3 Results for its Antibiotic Omadacyline - [at noodls] - 8914b644-3dc3-4314-a576-1bfc0f8e797a.pdf Media Release Zug, 17 June 2016 Paratek Pharmaceuticals (Nasdaq: PRTK), a listed company in the portfolio of HBM Healthcare Investments, yesterday announced that ...
06/17/16 08:42 AMBuzz Stocks: Smith & Wesson Holding Corp, Paratek Pharmaceuticals Inc, and Lumber Liquidators Holdings Inc
06/17/16 08:42 AMParatek Pharmaceuticals Inc. (PRTK) Is Climbing On Phase 3 Results
06/17/16 08:42 AMParatek Pharmaceuticals (PRTK) Announces Omadacycline Phase 3 Met All Primary, Secondary Endpoints in ABSSSI
06/16/16 06:11 PMParatek Pharmaceuticals Inc. (PRTK) Is Climbing On Phase 3 Results - RTT News
06/13/16 03:29 PMParatek Pharmaceuticals, Inc. Announces Participation in JMP Securities Life Sciences Conference - [at noodls] - BOSTON, June 01, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President and Chief Medical Officer, Evan Loh, MD, will participate in the JMP Securities ...
06/13/16 03:01 PMParatek to Present Omadacycline Microbiologic, Pharmacokinetic and Clinical Data at ASM Microbe 2016 - [GlobeNewswire] - -Biofilm, post-antibiotic effects, microbiologic surveillance and omadacycline in vitro activity against select pathogens to be presented. -Clinical PK and Modelling Strategies for omadacycline to be presented. ...
06/09/16 03:41 PMPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 06:30 PMHow Analysts Rated Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Last Week? - HNN
06/02/16 06:22 PMBroker Watchlist: Paratek Pharmaceuticals, Inc. (PRTK) - Share Trading News - Broker Watchlist: Paratek Pharmaceuticals, Inc. (PRTK)Share Trading News11/03/2014 – Ladenburg Thalmann began new coverage on Paratek Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 26 price target on the stock. The share price of Paratek Pharmaceuticals, Inc. (PRTK) was up +0.12% during ...and more »
06/02/16 12:03 PMParatek Pharmaceuticals, Inc. :PRTK-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -

Social

About Paratek Pharmaceuticals

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company's sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company's other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PRTK
  • CUSIP: 89354M10
Key Metrics:
  • Previous Close: $12.98
  • 50 Day Moving Average: $13.87
  • 200 Day Moving Average: $14.63
  • P/E Ratio: N/A
  • P/E Growth: -0.01
  • Market Cap: $228.31M
  • Beta: 0.48
  • Current Year EPS Consensus Estimate: $-5.62 EPS
  • Next Year EPS Consensus Estimate: $-3.5 EPS
Additional Links:
Paratek Pharmaceuticals (NASDAQ:PRTK) Chart for Saturday, July, 30, 2016